West Pharmaceutical Services (NYSE:WST) Issues Earnings Results

West Pharmaceutical Services (NYSE:WST) released its quarterly earnings results on Thursday. The medical instruments supplier reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.20 by $0.46, FiscalAI reports. West Pharmaceutical Services had a return on equity of 21.78% and a net margin of 18.81%. The company had revenue of $874.50 million for the quarter, compared to analysts’ expectations of $827.12 million. During the same period in the prior year, the firm earned $1.96 earnings per share. The firm’s revenue was up 8.7% compared to the same quarter last year.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

• Q3 results exceeded expectations: Revenue rose 8.7% reported and 11.9% organically to $874 million, while adjusted EPS increased 36% to $2.66. Management raised full-year 2026 revenue guidance to $3.41–$3.42 billion and adjusted EPS guidance to $9.38–$9.48.
• HVP and GLP-1 demand remained strong. HVP Components grew 20% organically, including GLP-1 growth well into the 30% range and high-teens growth outside GLP-1; the company also added more than 200 HVP upgrade projects this year.
• Profitability expanded significantly. Gross margin increased 310 basis points and adjusted operating margin rose 420 basis points year over year, supported by favorable HVP mix, pricing, plant execution and SG&A leverage.
• West is investing to support future growth through HVP finishing-capacity expansions in Europe and the U.S., while targeting CapEx of 6%–8% of revenue. New capacity is expected to come online over roughly 18–24 months, with existing facilities expected to support near-term demand.
• West Vantage remained in transition, with organic revenue down 6.6% as legacy programs, including a CGM program, rolled off faster than new higher-value programs ramped. In addition, the SmartDose 3.5 divestiture is expected to create an approximately 290-basis-point headwind to reported growth in 2027, while free cash flow was down about 5% year to date due mainly to higher receivables and inventory.

West Pharmaceutical Services Trading Down 0.9%

Shares of West Pharmaceutical Services stock opened at $412.73 on Friday. The company has a fifty day simple moving average of $367.76 and a 200-day simple moving average of $313.21. West Pharmaceutical Services has a 12-month low of $223.83 and a 12-month high of $438.27. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The stock has a market cap of $29.05 billion, a price-to-earnings ratio of 46.32, a PEG ratio of 2.75 and a beta of 1.13.

West Pharmaceutical Services Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Wednesday, November 11th will be given a dividend of $0.26 per share. The ex-dividend date is Tuesday, November 10th. This represents a $1.04 annualized dividend and a dividend yield of 0.3%. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. West Pharmaceutical Services’s payout ratio is presently 11.67%.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q3 results exceeded expectations: West reported adjusted earnings of $2.66 per share, above the $2.20 consensus estimate, while revenue rose 8.7% year over year to $874.5 million, surpassing the $827.1 million forecast. West Reports Third-Quarter 2026 Results
• Positive Sentiment: Higher 2026 outlook: Management raised full-year revenue guidance to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion and lifted adjusted EPS guidance to $9.38-$9.48 from $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: Strong high-value product demand: High-Value Product Components sales increased 19.7% and accounted for 53% of quarterly sales, supporting margin expansion and confidence in the company’s growth mix. West Pharma Q3 Earnings Rise on HVP Strength
• Positive Sentiment: Barclays raised its price target to $500 from $440 and maintained an “overweight” rating, implying additional upside based on the referenced share price. Barclays Raises West Pharmaceutical Price Target
• Neutral Sentiment: Institutional positioning was mixed, with several large funds adding shares while others reduced or exited positions. Recent insider activity also showed sales rather than purchases, though these transactions may not reflect the company’s operating outlook.
• Negative Sentiment: Valuation remains a risk after the rally, with the stock trading at a high earnings multiple. One analysis also cautioned that declining cash flow may leave the shares overvalued if earnings growth moderates. West Stock Could Be Overvalued

Insider Buying and Selling

In related news, VP Annette Favorite sold 2,524 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $365.00, for a total value of $921,260.00. Following the completion of the sale, the vice president directly owned 21,818 shares of the company’s stock, valued at $7,963,570. The trade was a 10.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 15,659 shares of company stock worth $5,443,749. 0.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on WST. Weiss Ratings raised West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. UBS Group lifted their target price on West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. TD Cowen boosted their price target on shares of West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a “buy” rating in a research note on Friday. Finally, BNP Paribas Exane assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 price target on the stock. Twelve equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $409.67.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.